Evidence map›Paper›PMID 35259129›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2022

High Rates of Pre-exposure Prophylaxis Eligibility and Associated HIV Incidence in a Population With a Generalized HIV Epidemic in Rakai, Uganda.

Victor Ssempijja, Gertrude Nakigozi, Robert Ssekubugu, Joseph Kagaayi, Godfrey Kigozi, Fred Nalugoda, Betty Nantume, James Batte, Grace Kigozi, Ping Teresa Yeh and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Victor SsempijjaClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD.ORCID 0000-0003-2609-6525
Gertrude NakigoziRakai Health Sciences Program, Entebbe, Uganda.
Robert SsekubuguRakai Health Sciences Program, Entebbe, Uganda.
Joseph KagaayiRakai Health Sciences Program, Entebbe, Uganda.
Godfrey KigoziRakai Health Sciences Program, Entebbe, Uganda.
Fred NalugodaRakai Health Sciences Program, Entebbe, Uganda.
Betty NantumeRakai Health Sciences Program, Entebbe, Uganda.
James BatteRakai Health Sciences Program, Entebbe, Uganda.
Grace KigoziRakai Health Sciences Program, Entebbe, Uganda.
Ping Teresa YehDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Hadijja NakawooyaRakai Health Sciences Program, Entebbe, Uganda.
David SerwaddaRakai Health Sciences Program, Entebbe, Uganda.
Thomas C QuinnDivision of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD.
Ronald H GrayRakai Health Sciences Program, Entebbe, Uganda.
Maria J WawerRakai Health Sciences Program, Entebbe, Uganda.
Kate M GrabowskiRakai Health Sciences Program, Entebbe, Uganda.
Larry W ChangRakai Health Sciences Program, Entebbe, Uganda.
Anja Van't HoogAmsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
Frank CobelensAmsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
Steven J ReynoldsRakai Health Sciences Program, Entebbe, Uganda.
Rakai Health Sciences Program · UGJohns Hopkins University · USAmsterdam Institute for Global Health and Development · NLNational Institutes of Health · US

Funding

International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Circumcision: HIV/STIs and behaviors in a RCT and post-RCT surveillance; RakaiU01AI075115 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2007 to 2011
$9.3M
Methods for Reducing Spatial Uncertainty and Bias in Disease SurveillanceR01AI102939 · NIAID · JOHNS HOPKINS UNIVERSITY · PI LESSLER, JUSTIN · 2013 to 2017
$4.6M
The role of penile bacteria and inflammation in HIV susceptibility; Rakai, UgandaR01AI123002 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI LIU, CINDY · 2016 to 2020
$3.3M
Enhanced Provision of Male Circumcision for HIV Prevention, Rakai, UgandaU01AI100031 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2012 to 2014
$3.2M
How sex, host microenvironment, and immune responses shape acquisition of genital bacteria that increase HIV riskR01DK131936 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI Cindy Liu · 2022 to 2026
$3.0M
HIV Incidence, Transmission Dynamics and Combination HIV Prevention: Rakai UgandaR01AI110324 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2014 to 2016
$2.4M
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZ01AI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI QUINN, THOMAS · 2008 to 2008
$2.2M
Penile Microbiome, Inflammation and HIV Susceptibility During Sexual Debut and Maturation Among Male AdolescentsR01AI128779 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2017 to 2020
$2.1M
Multidisciplinary Research Training to Understand and Reduce HIV Incidence in UgandaD43TW010557 · FIC · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2018 to 2022
$1.6M
Revealing women's hidden role as critical components of HIV transmission networks in Rakai, Uganda: an interdisciplinary approachK01AI125086 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRABOWSKI, MARY KATHRYN · 2016 to 2020
$638k
CCR NIH HHS HHSN261200800001CFIC NIH HHS D43 TW010557Intramural NIH HHS Z01 AI001040NCI NIH HHS HHSN261200800001ENCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INIAID NIH HHS K01 AI125086NIAID NIH HHS R01 AI102939NIAID NIH HHS R01 AI110324NIAID NIH HHS R01 AI123002NIAID NIH HHS R01 AI128779NIAID NIH HHS U01 AI075115NIAID NIH HHS U01 AI100031NIDDK NIH HHS R01 DK131936
6 · The paper itself

Abstract

backgroundThe utility of using pre-exposure prophylaxis (PrEP) eligibility assessments to identify eligibility in general populations has not been well studied in sub-Saharan Africa. We used the Rakai Community Cohort Study to conduct a cross-sectional analysis to estimate PrEP eligibility and a cohort analysis to estimate HIV incidence associated with PrEP eligibility.

methodsBased on Uganda's national PrEP eligibility tool, we defined eligibility as reporting at least one of the following HIV risks in the past 12 months: sexual intercourse with more than one partner of unknown HIV status; nonmarital sex act without a condom; sex engagement in exchange for money, goods, or services; or experiencing genital ulcers. We used log-binomial and modified Poisson models to estimate prevalence ratios for PrEP eligibility and HIV incidence, respectively.

findingsWe identified 12,764 participants among whom to estimate PrEP eligibility prevalence and 11,363 participants with 17,381 follow-up visits and 30,721 person-years (pys) of observation to estimate HIV incidence. Overall, 29% met at least one of the eligibility criteria. HIV incidence was significantly higher in PrEP-eligible versus non-PrEP-eligible participants (0.91/100 pys versus 0.41/100 pys; P < 0.001) and independently higher in PrEP-eligible versus non-PrEP-eligible female participants (1.18/100 pys versus 0.50/100 pys; P < 0.001). Among uncircumcised male participants, HIV incidence was significantly higher in PrEP-eligible versus non-PrEP-eligible participants (1.07/100 pys versus 0.27/100 pys; P = 0.001), but there was no significant difference for circumcised male participants.

interpretationImplementing PrEP as a standard HIV prevention tool in generalized HIV epidemics beyond currently recognized high-risk key populations could further reduce HIV acquisition and aid epidemic control efforts.

Indexed as

Anti-HIV AgentsEpidemicsHIV InfectionsPre-Exposure ProphylaxisCohort StudiesCross-Sectional StudiesFemaleHomosexuality, MaleHumansIncidenceMaleUgandaAnti-HIV Agents

Identifiers

PMID35259129
PMCPMC9177156
OpenAlexW4220815440

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.